Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | UNK | Unknown | PO / MO |
The patient took two doses of Vivotif about two months ago and stopped, not completing the series; Case reference number US-BN-2025-000876 is a spontaneous case initially received from nurse via agency (reference number: USBAV25-0939) on 25-Apr-2025 and concerns a patient of unspecified age and gender. The patient's medical history and concomitant medication details were not provided. On unspecified dates, the patient took two doses of Vivotif (batch number: unknown) orally, at unknown dose, for indication protection against typhoid fever and stopped taking and did not completed the series (explicitly coded as 'Incomplete course of administration'). At the time of the initial report, it was unknown if patient experienced any adverse events due to Vivotif. Additional information received from nurse via agency on 26-Apr-2025. New information included update for gender, gender confirmed to be unknown.; Reporter's Comments: This case concerned a patient of unknown age/age group and gender. On unspecified dates, the patient took two doses of Vivotif vaccine orally, at unknown dose, for indication protection against typhoid fever and stopped taking and did not complete the series which is considered as incomplete course of vaccination. At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. Incomplete course of vaccination is considered as listed as per company convention. The patients' medical history and concomitant medication details were not provided. Incomplete course of vaccination is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: This case concerned a patient of unknown age/age group and gender. On unspecified dates, the patient took two doses of Vivotif vaccine orally, at unknown dose, for indication protection against typhoid fever and stopped taking and did not complete the series which is considered as incomplete course of vaccination. At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. Incomplete course of vaccination is considered as listed as per company convention. The patients' medical history and concomitant medication details were not provided. Incomplete course of vaccination is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: NONE